Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04137263 · ClinicalTrials.gov registry record · NA
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
A NA study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT04137263 is a NA study that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 24 participants.
The verdict
NCT04137263, a NA study, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy, of D.O.S.E formulations in the treatment of melasma and cutaneous signs of aging.
Interventions
- OTHER DOSE formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2020-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04137263
The ClinicalTrials.gov registry entry for NCT04137263 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DOSE formulation is the first listed.
NCT04137263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04137263 about?
NCT04137263 is a clinical study titled "Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging". The primary objective is to evaluate the efficacy, of D.O.S.E formulations in the treatment of melasma and cutaneous signs of aging.
What is the current status of trial NCT04137263?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2019-10-01. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT04137263?
The interventions under investigation include: DOSE formulation (OTHER).
Who is sponsoring clinical trial NCT04137263?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.